Authors
- Vedran Pašara — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0002-6587-2315
- Ivan Prepolec — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0001-5870-202X
- Richard Matasić — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0003-1289-1704
- Borka Pezo-Nikolić — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0002-0504-5238
- Miroslav Krpan — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0002-0639-953X
- Mislav Puljević — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0003-1477-2581
- Davor Puljević — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0003-3603-2242
- Martina Lovrić Benčić — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0001-8446-6120
- Davor Miličić — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0001-9101-1570
- Vedran Velagić — University of Zagreb School of Medicine, Zagreb, Croatia — ORCID: 0000-0001-5425-5840
Keywords
His-bundle, pacing therapy, complication rates
DOI
https://doi.org/10.15836/ccar2021.63Full Text
His bundle pacing activates the ventricles physiologically by direct stimulation of the His-Purkinje cardiac conduction system. ( 1 ) It was first described in the 1970s, first studies were reported in the early 2000s followed by technological advances that led to its widespread uptake and growing evidence base. ( 1 , 2 ) This retrospective study aimed to evaluate His-bundle lead implantation program in our centre. A total of 116 consecutive patients (63.8% male, 65.4 ± 13.6 years) who underwent His-bundle lead implantation in our centre from November 2018 until November 2020 were analyzed. Among these patients, over two-thirds (69.8%) had arterial hypertension, 43.1% had dyslipidemia and 29.3% had diabetes. Nearly half of patients (49.1%) had chronic heart failure, 26.7% had coronary artery disease and 8.6% had prior myocardial infarction. 40.5% of patients had atrial fibrillation. His-bundle lead implantation was achieved in 105 (90.5%) of all patients, while the rest of the procedures were aborted and ended with right ventricle lead placement. Ten (8.6%) patients had postprocedural complications, six of which were resolved without lead extraction. Only one patient had a device-associated infection. With this analysis, we showed that the results of our His-bundle lead implantation program, regarding success and complication rates, are similar to available literature data. ( 1 , 2 )